- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01059877
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
What hypotheses are you testing?
We are seeking to determine if the provision of brief, repeated exposure to 1072nm infrared stimulation of the cortex surface improves cognitive and behavioral functioning as indicated by normalization of EEG activity, increased cerebral oxygenation and demonstrated improvement on standardized neuropsychological measures.
Intensive near infrared stimulation has been shown to be effective in accelerating healing of injuries and functional modification including increasing blood flow and perfusion. Dementia research has suggested that hypoperfusion is a significant underlying mechanism in the progression of dementia. Infrared spectroscopy has been shown effective in the non-invasive measurement of changes in cerebral oxygenation and perfusion. This study therefore seeks to explore whether the increasing of regional cerebral perfusion and oxygenation using infrared light stimulation will result in improved cognitive and behavioral functioning.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, United States, 19462
- Quietmind Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 50 - 85 years.
- Have established cognitive impairment, Mini Mental Status Examination (MMSE) score between 15- 25 (from a possible score of 30).
- Generally healthy otherwise as indicated by recent physical examination.
- Have a caregiver/informant who has cared for the patient at least 5 days a week and is willing to attend study visits and provide information about the patient.
- If taking any psychotropic medication should have been stable for the previous 3 months.
- Must have had B12, folic acid, full blood count and ferritin screen within the previous 6 months or be on B12 and/or folic acid replacement.
Exclusion Criteria:
- Uncontrolled or unstable chronic illness, e.g., hypertension, chronic obstructive pulmonary disease (COPD).
- Diagnosed actively growing intracranial pathology (tumors etc).
- An associated psychotic illness.
- Misusing illegal substances or alcohol.
- On regular systemic steroids or anti-metabolites.
- Systemic malignancies and/or space occupying lesions in the brain.
- Not fluent in English.
- Depressed as assessed by Beck Depression Inventory score.
- Epilepsy.
- Lacking the capacity to give informed consent.
- Previous history of stroke or heart attack.
- History of aggression or violence.
- Inability to travel to the research venue for multiple assessments.
- A history of major psychiatric illness, seizure disorder, or physical illness that would compromise their participation in a daily treatment regimen.
- A participant may be disqualified if their performance is above the normative mean or below the lowest interpretable score of neuropsychological tests provided during the initial assessment (see #6, Sources of research material obtained from study participants, below).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1072nm Infrared Photobiomodulation
Received treatment for dementia with transcranial 1072nm infrared light stimulation.
|
1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
Other Names:
|
Placebo Comparator: Placebo
Placebo device simulated transcranial photobiomodulation
|
Device mounted and procedure followed but with no stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.
Time Frame: Post-tx (total intervention period = 28 days) scores to be compared to baseline scores.
|
Delayed Word Recall is a subscale of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), a measure of cognitive impairment.
Higher scores indicate greater impairment.
Range: 0-10.
Measures were taken within 72 hours of the first day of treatment and within 72 hours following the 28th day of treatment.
Outcome measure was calculated by subtracting pretest from post test ADAS-Cog measurements.
|
Post-tx (total intervention period = 28 days) scores to be compared to baseline scores.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marvin H Berman, Ph.D, Quietmind Foundation
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QMF-MID12610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on 1072nm infrared Photobiomodulation
-
Gaitway NeurophysioRecruitingDisease | Parkinson'sCanada
-
Massachusetts General HospitalRecruiting
-
Eli Sprecher, MDRecruitingInflammatory Bowel Diseases | Crohn Disease | IBDIsrael
-
China Medical University HospitalMinistry of Science and Technology, TaiwanCompletedMajor Depressive Disorder | Oxidative StressTaiwan
-
University of Nove de JulhoCompleted
-
MindLight, LLCCompletedOpioid-use Disorder | Depression, Anxiety | CravingUnited States
-
University of FloridaParkinson's Foundation; FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMERRecruiting
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
University of Nove de JulhoUnknown
-
University of Nove de JulhoNot yet recruitingPostmenopausal Symptoms